全文获取类型
收费全文 | 3622篇 |
免费 | 261篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 47篇 |
儿科学 | 101篇 |
妇产科学 | 116篇 |
基础医学 | 517篇 |
口腔科学 | 181篇 |
临床医学 | 224篇 |
内科学 | 908篇 |
皮肤病学 | 132篇 |
神经病学 | 217篇 |
特种医学 | 98篇 |
外科学 | 638篇 |
综合类 | 24篇 |
一般理论 | 2篇 |
预防医学 | 285篇 |
眼科学 | 22篇 |
药学 | 174篇 |
中国医学 | 24篇 |
肿瘤学 | 180篇 |
出版年
2023年 | 12篇 |
2022年 | 28篇 |
2021年 | 89篇 |
2020年 | 68篇 |
2019年 | 93篇 |
2018年 | 95篇 |
2017年 | 79篇 |
2016年 | 90篇 |
2015年 | 89篇 |
2014年 | 100篇 |
2013年 | 132篇 |
2012年 | 166篇 |
2011年 | 199篇 |
2010年 | 125篇 |
2009年 | 105篇 |
2008年 | 185篇 |
2007年 | 191篇 |
2006年 | 181篇 |
2005年 | 146篇 |
2004年 | 173篇 |
2003年 | 145篇 |
2002年 | 140篇 |
2001年 | 117篇 |
2000年 | 131篇 |
1999年 | 98篇 |
1998年 | 40篇 |
1997年 | 27篇 |
1996年 | 28篇 |
1995年 | 24篇 |
1994年 | 23篇 |
1993年 | 15篇 |
1992年 | 78篇 |
1991年 | 58篇 |
1990年 | 64篇 |
1989年 | 59篇 |
1988年 | 69篇 |
1987年 | 47篇 |
1986年 | 54篇 |
1985年 | 54篇 |
1984年 | 37篇 |
1983年 | 35篇 |
1982年 | 19篇 |
1981年 | 12篇 |
1979年 | 14篇 |
1978年 | 15篇 |
1974年 | 12篇 |
1972年 | 20篇 |
1971年 | 18篇 |
1968年 | 12篇 |
1967年 | 12篇 |
排序方式: 共有3890条查询结果,搜索用时 328 毫秒
61.
62.
Association of Guideline‐concordant Acute Asthma Care in the Emergency Department With Shorter Hospital Length of Stay: A Multicenter Observational Study 下载免费PDF全文
63.
Tspan33 is Expressed in Transitional and Memory B Cells,but is not Responsible for High ADAM10 Expression 下载免费PDF全文
C. A. Prez‐Martínez J. L. Maravillas‐Montero I. Meza‐Herrera F. Vences‐Cataln A. Zlotnik L. Santos‐Argumedo 《Scandinavian journal of immunology》2017,86(1):23-30
Tetraspanins are a family of transmembrane proteins that form membrane microdomains. They play important roles in migration, adhesion and other cellular processes. TspanC8, a subfamily of tetraspanins, was found to associate and promote ADAM10 trafficking and cell surface localization. One of its members, Tspan33, is expressed in activated B cells. Using RT‐PCR and flow cytometry, we analysed the pattern of expression of Tspan33 in B cells from healthy donors. We found Tspan33 expression in early and late stages of B cell development. However, Tspan33 expression did not correlate with ADAM10 surface expression. We also found expression of Tspan33 early in the activation process. Given its predominant expression in activated B cells and in several lymphomas, but not in naive B cells, we hypothesize that Tspan33 could be a potential target for therapeutic purposes. 相似文献
64.
Carmona L Hernández-García C Vadillo C Pato E Balsa A González-Alvaro I Belmonte MA Tena X Sanmartí R;EMECAR Study Group 《The Journal of rheumatology》2003,30(7):1436-1439
OBJECTIVE: To quantify the risk of tuberculosis (TB) in an unselected sample of patients with rheumatoid arthritis (RA) compared to the risk in the general population. METHODS: The incidence of TB in the general population of Spain was obtained from the National Network of Epidemiological Surveillance reports. The incidence of TB was ascertained from a cohort of 788 patients with RA selected randomly from the registries of 34 participating centers throughout Spain. A patient was considered a TB case only if information about disease symptoms, microorganism identification, and TB treatment were confirmed in the clinical records. The relative risk of TB in RA was calculated by dividing the standardized mean incidence of TB from 1990 to 2000 in the RA cohort by the mean incidence of TB in Spain during the same years. RESULTS: The mean incidence of TB in the general population of Spain from 1990 to 2000 was 23 cases per 100,000. Seven cases of TB were identified in the RA cohort, yielding a mean annual incidence (1990-2000) of 134/100,000 patients. The incidence risk ratio of pulmonary TB in patients with RA compared to the general population is 3.68 (95% CI 2.36-5.92). CONCLUSION: We found a 4-fold increased risk of TB infection in patients diagnosed with RA. These results might help to interpret the magnitude of the problem attributable to the introduction of new therapies in RA. 相似文献
65.
Leticia Leon Marta Redondo Alberto Garcia-Vadillo Miguel A. Perez-Nieto Luis Rodriguez-Rodriguez Juan A. Jover Isidoro Gonzalez-Alvaro Lydia Abasolo 《Rheumatology international》2016,36(11):1549-1555
Individualized treatment of rheumatoid arthritis (RA) based on genetic/serologic factors is increasingly accepted. Moreover, patients are more actively involved in the management of their disease. However, personality has received little attention with respect to perception of the need and adherence to treatment. Our objective was to evaluate whether patient personality was associated with the acceptance or rejection of more aggressive early treatment. We performed a cross-sectional study in two hospitals with early arthritis clinics where sociodemographic, clinical, and therapeutic variables are systematically recorded. Patients completed Eysenck Personality Questionnaire, Multidimensional Health Locus of Control, Pain-Related Self-Statement Scale and Pain-Related Control Scale. Aggressive treatment was considered if patients received more than two DMARDs or biological agents during the first year of follow-up. Multivariate logistic regression analysis was performed to determine predictors of aggressive treatment. One hundred seventy-six RA patients were included (80 % women, disease begin median age 55 years). Treatment was considered aggressive in 57.9 % of the sample. Scores were high in extraversion in 50.8 % of patients, neuroticism in 29.5 % and psychoticism in 14.7 %. Neuroticism was the only factor associated with aggressive treatment, which was less probable (p = 0.04, OR = 0.40). Neuroticism also decreased the possibility of receiving a combination of biologics and DMARDs (p = 0.04, OR = 0.28). Patients with high scores on neuroticism are more worried, obsessive and hypochondriac, leading them to reject more aggressive therapy. It is important to educate about their disease so that they will accept more aggressive approaches in clear cases of poor outcome. 相似文献
66.
67.
U Juárez Herrera L A Lasses y Ojeda M C López E Chuquiure H González Pacheco J Carrillo Calvillo C Martínez Sánchez E Lupi Herrera 《Archivos del Instituto de Cardiología de México》1998,68(5):411-420
OBJECTIVE: To review the results and complications of thrombolysis in patients with acute myocardial infarction (AMI) and its complications. METHODS: Since june 1989 to august 1994 we studied patients with AMI, who underwent thrombolysis. Clinical characteristics, complications and angiographic results are described. RESULTS: Of the total population 86.3% patients received Streptokinase (SK) and 13.7% recombinant tissue plasminogen activator (rt-PA). In 20 patients the age was under 40 years, 373 between 40-70 years, and 80 patients over 70 years. 84% were men and 16% women. 72% had smoking habit; 21% diabetes mellitus, 43% hypertension, 54% had previous angina and previous AMI in 22%. The location of AMI was anterior in 234 patients and 239 inferior. In 63% enzyme washout was observed, and rapid electrocardiographic evolution in 81%. Postthrombolisis arrhythmias was observed in 64.7%. Major bleeding in 11.8% and central nervous system hemorrhage in 0.4% only with rt-PA. Postinfarction angina in 22%, and re-infarction in 4%. Cardiac rupture in 1.4%, with shock and death. Mitral insufficiency in 2.1% demonstrated by echocardiogram. Coronary angiography was done in 373 patients (80%), of which 50.7% was made in the first 5 days. The culprit artery was anterior descending in 273 patients and right coronary in 95. Left ventricular dysfunction was seen in 23% in patients with anterior AMI, and 5% with inferior AMI. Cardiogenic shock was seen in 7%. Coronary artery bypass grafting was undertaken in 106 patients and coronary angioplasty in 67. The ten days mortality was 8.8%, principally due to cardiogenic shock, ventricular arrhythmias and ventricular rupture. CONCLUSIONS: The usefull permeability in the culprit artery was obtained in 40%, who had coronary angiography done 145 hours posthrombolysis. Mortality was under 10% in this study. 相似文献
68.
Ji Yun Song Puya Aravand Sergei Nikonov Lanfranco Leo Arkady Lyubarsky Jeannette L. Bennicelli Jieyan Pan Zhangyong Wei Ivan Shpylchak Pamela Herrera Daniel J. Bennett Nicoletta Commins Albert M. Maguire Jennifer Pham Anneke I. den Hollander Frans P.M. Cremers Robert K. Koenekoop Ronald Roepman Jean Bennett 《Molecular therapy》2018,26(6):1581-1593
69.